Moment of Truth now for Koos and ENTB. I was surprised by the rs ratio but will like the PPS potential of 16M OS. Great position to be in IF(key word here) there is substantial news AND IF there are continued developments....WHICH it seems like there will be with this move...Otherwise, well I wont go there now.
The OS had to be rationalized and couldn't stay at billions at this fledgling level, again IF, the company wants to be recognized..i.e share value. As frustrating as Koos has been over the years he has hung in there and continued to move his entities forward and has recruited some top talent to work for him. Credit due.
ENTB has Christine Ichim's novel approach that she developed, connections to the other biotech companies to leverage, industry connections, plus announced discussions for acquiring drug nanotech delivery, and movement towards BOTH animal and human applications BOTH with huge market potentials. So I believe you are on the right track Bucks. We will find out soon enough it seems.
GLTA.